Predictive wild-type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy

被引：0
|
作者：
Russell, Mike
Lowenstein, Cassandra L.
Zhang, Xuqing
Roach, Jeremy
Song, Jianing
Nagilla, Rakesh
Orth, Peter
Tudor, Matt
Deng, Qiaolin
Sui, Zhihua
Strickland, Corey
Jolivette, Larry J.
Priestley, E. Scott
Mohammad, Helai P.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A052
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
    Pinto, Carmine
    Orlandi, Armando
    Normanno, Nicola
    Maiello, Evaristo
    Calegari, Maria A.
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria G.
    Pini, Sara
    Bergamo, Francesca
    Tonini, Giuseppe
    Avallone, Antonio
    Latiano, Tiziana P.
    Rosati, Gerardo
    Cogoni, Alessio Aligi
    Ballestrero, Alberto
    Zaniboni, Alberto
    Roselli, Mario
    Tamberi, Stefano
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1278 - 1287
  • [32] Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study
    Xu, Chang
    Ren, Jing
    Liu, Changqing
    Gai, Yi
    Cheng, Xiangyu
    Wang, Yusheng
    Wang, Guangyu
    ANTI-CANCER DRUGS, 2025, 36 (05) : 383 - 393
  • [33] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [34] The impact of toxicity and efficacy on quality of life in KRAS wild-type metastatic colorectal cancer patients treated with first-line chemotherapy plus cetuximab
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Von Hohnhorst, P.
    Esser, R.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S518 - S518
  • [35] Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
    Ding, Ke-Feng
    Liu, Yue
    Xiao, Qian
    He, Jinjie
    Hu, Hanguang
    Du, Jinlin
    Zhu, Yuping
    Chen, Jiaqi
    Liu, Zhuo
    Wang, Jianping
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Liao, Xiujun
    Wang, Jianwei
    Cai, Yibo
    Cai, Cheng
    Jin, Zhekang
    Yuan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 138 - 138
  • [36] Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study
    Chang, Yu-Tang
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Shuan-Yuan
    Huang, Ching-Wen
    Wang, Jaw-Yuan
    NUTRIENTS, 2023, 15 (13)
  • [37] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
    Zekri, Jamal
    Baghdadi, Mohammed Abbas
    Ibrahim, Refaei Belal
    Meliti, Abdelrazak
    Sobahy, Turki M.
    ECANCERMEDICALSCIENCE, 2022, 16 : 1 - 16
  • [38] Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
    Kasper, Stefan
    Foch, Caroline
    Messinger, Diethelm
    Esser, Regina
    Lamy, Francois-Xavier
    Rothe, Vivien
    Chen, Wenfeng
    Cheng, Ann-Lii
    Rouyer, Magali
    Brodowicz, Thomas
    Zielinski, Christoph
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 291 - 301
  • [39] Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
    Liu, Yue
    Ding, Kefeng
    Xiao, Qian
    He, Jinjie
    Hu, Hanguang
    Du, Jinlin
    Zhu, Yuping
    Chen, Jiaqi
    Liu, Zhuo
    Wang, Jianping
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Liao, Xiujun
    Wang, Jianwei
    Cai, Yibo
    Cai, Cheng
    Jin, Zhekang
    Yuan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 131 - 131
  • [40] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
    Han, Jiaqi
    Xiao, Desheng
    Tan, Chongqing
    Zeng, Xiaohui
    Hu, Huabin
    Zeng, Shan
    Jiang, Qin
    She, Longjiang
    Yao, Linli
    Li, Li
    Tang, Lanhua
    Ma, Jian
    Huang, Jin
    Shen, Liangfang
    CANCER CONTROL, 2020, 27 (01)
12345